Medtech titan St. Jude Medical slides 7% after the FDA releases a report slamming the device maker's Durata pacemaker leads.
MASSDEVICE ON CALL — Medical device maker St. Jude Medical's (NYSE:STJ) shares lost more than 10% in one day after the FDA released a report detailing potential issues with the tech giant's Durata pacemaker leads.
STJ shares on Wednesday, November 21, opened at $33.76 prior to the publication of the FDA's report. Shares tumbled 7.1% by the end of the day, closing at $31.76 and along the way notching a new 52-week low of $30.25, a 10.4% dip.
The FDA's report detailed 11 problems with manufacturing at St. Jude's Sylar, Calf., plant, which manufactures the company's Durata pacemaker leads.
Investors are watching closely for signs of problems with the next-generation Durata leads after the St. Paul, Minn.-based medical device company recalled some of its Riata leads last year. Last month CEO Daniel Starks cautioned that St. Jude risked a warning from the federal watchdog agency over the Sylmar plant.
STJ shares regained some of their lost value, closing at $32.03 on Friday, still a 5.1% loss from Thursday's open.
Airport X-rays versus medical devices
Airport body and luggage X-ray scanners may damage some diabetes devices, including insulin pumps and continuous glucose monitors, according to editors of the journal Diabetes Technology & Therapeutics.
BD, Rite Aid team up with EPA for safer needles
Healthcare company Becton Dickinson & Co. (NYSE:BDX) teamed up with Rite Aid to develop a program with the Dept. of Environmental Protection, aiming to reduce injuries associated with medical sharps such as needles and other devices.
Mainstay Medical looks to raise up to $42 million with an initial public offering on the EuroNext...
Philips voluntarily suspends manufacturing at an Ohio facility after an FDA investigation turns up "...
Hospitals are using Google's reality-augmenting Glass technology to help sick kids and better treat...
Former Stryker executive Mark Foldy, who pleaded guilty last year for his part in an insider trading...
Sales and profits were down during the 1st quarter for GE Healthcare, which cited "market volatility...